Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02772718 · ClinicalTrials.gov registry record · Phase 2

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

A Phase 2 study, sponsored by Xoma (US).

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT02772718 is a Phase 2 study that has completed, run by Xoma (US). The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02772718, a Phase 2 study, has completed, sponsored by Xoma (US).

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and clinical pharmacology of XOMA 358 in patients with hypoglycemia after gastric bypass surgery.

Interventions

  • DRUG XOMA 358 single dose level A
  • DRUG XOMA 358 single dose level B
  • DRUG XOMA 358 single dose level C
  • DRUG XOMA 358 multiple dose level 1

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2016-04
Est. Completion 2021-05
Phase Phase 2

Sponsor

Xoma (US)

20 total trials

What the Registry Record Tells You About NCT02772718

The ClinicalTrials.gov registry entry for NCT02772718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which XOMA 358 single dose level A is the first listed.

NCT02772718 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02772718 about?

NCT02772718 is a clinical study titled "An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery". The purpose of this study is to evaluate the safety and clinical pharmacology of XOMA 358 in patients with hypoglycemia after gastric bypass surgery.

What is the current status of trial NCT02772718?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-04. Estimated completion is 2021-05.

What interventions are being tested in trial NCT02772718?

The interventions under investigation include: XOMA 358 single dose level A (DRUG), XOMA 358 single dose level B (DRUG), XOMA 358 single dose level C (DRUG), XOMA 358 multiple dose level 1 (DRUG).

Who is sponsoring clinical trial NCT02772718?

This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.